Literature DB >> 10899727

Refractory sprue syndrome with clonal intraepithelial lymphocytes evolving into overt enteropathy-type intestinal T-cell lymphoma.

S Daum1, M Hummel, D Weiss, M Peters, B Wiedenmann, F Schäper, H Stein, E O Riecken, H Foss.   

Abstract

INTRODUCTION: Recently, patients with refractory sprue have been shown to contain a clonal proliferation of phenotypically abnormal intraepithelial lymphocytes in their intestine. Whether this signifies early enteropathy-type intestinal T-cell lymphoma (EITCL) or a reactive condition is not clear. We report on a patient presenting with the findings of refractory sprue who subsequently developed overt EITCL.
MATERIAL AND METHODS: Duodenal biopsies from 1997 (refractory sprue) and duodenal and jejunal biopsies from 1998 (intestinal T-cell lymphoma) were compared by immunohistochemistry and PCR for the detection of T-cell receptor (TCR)-gamma gene rearrangements. Clonal PCR products were sequenced.
RESULTS: The duodenal biopsies from both 1997 and 1998 and the jejunal tumor biopsy showed villus atrophy and an increase of intraepithelial lymphocytes with an abnormal immunophenotype (CD3+, CD4-, CD8- and TCR-beta-). In all duodenal specimens including the one from 1997, and the jenunal tumor biopsy, an identical clonal amplificate was detected by enzymatic amplification of the TCR-gamma gene.
CONCLUSION: These data suggest that refractory sprue containing a clonal proliferation of phenotypically abnormal intraepithelial lymphocytes may represent an early manifestation of EITCL. The detection of immunohistochemical negativity for several antigens normally found on intraepithelial lymphocytes such as CD8 or the TCR-beta chain in combination with clonal T-cell populations by PCR may be helpful in identifying refractory sprue with a malignant transformation. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10899727     DOI: 10.1159/000007779

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  14 in total

1.  Evaluation of Cladribine treatment in refractory celiac disease type II.

Authors:  Greetje J Tack; Wieke H M Verbeek; Abdul Al-Toma; Dirk J Kuik; Marco W J Schreurs; Otto Visser; Chris J J Mulder
Journal:  World J Gastroenterol       Date:  2011-01-28       Impact factor: 5.742

Review 2.  Classification and management of refractory coeliac disease.

Authors:  Alberto Rubio-Tapia; Joseph A Murray
Journal:  Gut       Date:  2010-04       Impact factor: 23.059

Review 3.  An approach to duodenal biopsies.

Authors:  S Serra; P A Jani
Journal:  J Clin Pathol       Date:  2006-05-05       Impact factor: 3.411

4.  Successful treatment of enteropathy-associated T cell lymphoma with autologous stem cell transplant.

Authors:  Catherine Rongey; Ivana Micallef; Thomas Smyrk; Joseph Murray
Journal:  Dig Dis Sci       Date:  2006-06       Impact factor: 3.199

5.  [Enteropathy type T-cell lymphomas: pathology and pathogenesis].

Authors:  A Zettl; T Rüdiger; H K Müller-Hermelink
Journal:  Pathologe       Date:  2007-02       Impact factor: 1.011

6.  Enteropathy associated T cell lymphoma: common in coeliac disease.

Authors:  Gabrielle Christina Colleran; Kevin Christopher Cronin; Mary Casey; Fadel Bennani; Iqdam Tobbia; Kevin Barry
Journal:  BMJ Case Rep       Date:  2009-02-23

7.  Chromosomal gains at 9q characterize enteropathy-type T-cell lymphoma.

Authors:  Andreas Zettl; German Ott; Angela Makulik; Tiemo Katzenberger; Petr Starostik; Thorsten Eichler; Bernhard Puppe; Martin Bentz; Hans Konrad Müller-Hermelink; Andreas Chott
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

Review 8.  Celiac disease: prevalence, diagnosis, pathogenesis and treatment.

Authors:  Naiyana Gujral; Hugh J Freeman; Alan B R Thomson
Journal:  World J Gastroenterol       Date:  2012-11-14       Impact factor: 5.742

9.  Survival in refractory coeliac disease and enteropathy-associated T-cell lymphoma: retrospective evaluation of single-centre experience.

Authors:  A Al-Toma; W H M Verbeek; M Hadithi; B M E von Blomberg; C J J Mulder
Journal:  Gut       Date:  2007-04-30       Impact factor: 23.059

10.  Anti-calreticulin immunoglobulin A (IgA) antibodies in refractory coeliac disease.

Authors:  D Sánchez; L Palová-Jelínková; J Felsberg; M Simsová; A Pekáriková; B Pecharová; I Swoboda; T Mothes; C J J Mulder; Z Benes; H Tlaskalová-Hogenová; L Tucková
Journal:  Clin Exp Immunol       Date:  2008-07-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.